Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. - Suppr | 超能文献

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

作者信息

Maier Christiane

机构信息

Institut für Humangenetik, Universität Ulm, Ulm, Germany.

出版信息

Eur Urol. 2007 Oct;52(4):1088-9. doi: 10.1016/j.eururo.2007.04.010.

DOI:10.1016/j.eururo.2007.04.010

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

Eur Urol. 2007 Oct;52(4):1088-9. doi: 10.1016/j.eururo.2007.04.010.

2

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.

Eur Urol. 2007 Oct;52(4):1087-8. doi: 10.1016/j.eururo.2007.04.009.

3

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.SRD5A2基因中的低活性V89L变体与侵袭性前列腺癌风险相关：对使用5α-还原酶抑制剂的化学预防试验中观察到的不良反应的一种解释。

Eur Urol. 2007 Oct;52(4):1082-7. doi: 10.1016/j.eururo.2007.04.008. Epub 2007 Apr 13.

4

V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.II型5α-还原酶基因（SRD5A2）的V89L多态性、内源性性激素与前列腺癌风险

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):286-91. doi: 10.1158/1055-9965.EPI-07-0238.

5

A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.类固醇5-α还原酶基因（SRD5A2）中的错义替换A49T与芬兰的前列腺癌无关。

Br J Cancer. 2001 May 18;84(10):1344-7. doi: 10.1054/bjoc.2001.1789.

6

Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.人前列腺癌组织中体细胞类固醇5α-还原酶（SRD5A2）突变的鉴定与特征分析

Oncogene. 2004 Sep 23;23(44):7399-405. doi: 10.1038/sj.onc.1207922.

7

The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.SRD5A2基因V89L多态性与早发性前列腺癌男性患者的疾病严重程度相关。

Prostate. 2008 Dec 1;68(16):1798-805. doi: 10.1002/pros.20842.

8

Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.关于“降低前列腺癌风险的药理学方法”的编辑评论

Eur Urol. 2009 May;55(5):1073-4. doi: 10.1016/j.eururo.2009.01.038. Epub 2009 Feb 5.

9

Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.有待商榷。议题：使用5α还原酶抑制剂预防前列腺癌是否可行。

Eur Urol. 2006 Feb;49(2):396-400. doi: 10.1016/j.eururo.2005.12.059.

10

Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.厄瓜多尔人群中类固醇5α-还原酶II型（SRD5A2）基因多态性、前列腺癌风险与前列腺肿瘤病理特征之间的关联。

Cancer Genet Cytogenet. 2009 Mar;189(2):71-6. doi: 10.1016/j.cancergencyto.2008.09.012.

引用本文的文献

1

Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.无偏数据挖掘识别出可预测非惰性 Gleason 评分 7 前列腺癌的细胞周期转录本。

BMC Urol. 2019 Jan 7;19(1):4. doi: 10.1186/s12894-018-0433-5.